Novocure Announces Positive Phase 2 Clinical Trial Results for Mesothelioma Patients

On April 17, Novocure (NVCR) announced positive results from its Phase 2 clinical trial for the treatment of mesothelioma. Patients who received Tumor Treatment Fields in addition to standard chemotherapy treatment experienced improvements in overall survival and progression. Novocure is a global oncology company developing its proprietary technology called Tumor Treating Fields, which use electric fields to disrupt solid tumor cancer cell division.


Rocket Tickers detected the event and issued an alert at 7:30 am. The next trade took place at 7:31 for $21.90. Regular market trading opened for the day at $22.15. The stock price continued to rise throughout the day before closing at $23.25. Over the next five trading sessions, the stock price experienced even more gains. Novacure closed at $24.48 on April 24, which is a gain of almost 12% following the event.

Visit the Knowledge Center for more information about clinical trials and how to trade them.

Check out our latest Live Webinar which provides more information about price patterns after clinical trial announcements and how to trade them.

Subscribe here if you would like to start receiving these signals in real-time and start trading!